Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Oct 02, 2021 9:01am
167 Views
Post# 33957230

RE:RE:CEO bought 100k - just filed

RE:RE:CEO bought 100k - just filed100k in shares will do nothing here to support the share price. Warrant holders would be looking for more of a differential than 2-3 cents on their exercise price. As I said, either we are 5-6 million less in dilution by October 16 or the hammer drops and something goes, along with adding $1M to coffers. Either way, we are better off.

The sedi confirms it was a buy on open market, pure and simple signal to us in my view of confidence without contravening of insider trading regs while they wait for concrete contract material documentation to be presented, which could technically come as early as next week, or later, or not at all. He knows investors have been more than patient and I see this as his way to signal something important to shareholders. I see no other motivation here. I am 100% ok to be wrong here. GLTA.
<< Previous
Bullboard Posts
Next >>